NCT07885618 Factors Influencing Outcomes in ECMO and Impella Patients: Metabolic and Thyroid Hormone Dynamics
| NCT ID | NCT07885618 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gottsegen National Cardiovascular Institute |
| Condition | Cardiogenic Shock |
| Study Type | OBSERVATIONAL |
| Enrollment | 160 participants |
| Start Date | 2026-08-17 |
| Primary Completion | 2030-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 160 participants in total. It began in 2026-08-17 with a primary completion date of 2030-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, single-center, consecutive observational study evaluates clinical, metabolic, and endocrine factors influencing survival and clinical outcomes in adult patients undergoing temporary mechanical circulatory support at the Cardiovascular Intensive Care Unit of Gottsegen Gyorgy National Cardiovascular Institute. While traditional cardiovascular risk factors in critically ill patients are well established, non-cardiovascular variables such as endocrine dysfunction, previous functional and nutritional status, metabolic parameters and clinical complications significantly impact short- and long-term outcomes. The study consecutively enrolls all eligible adult patients admitted to the intensive care unit requiring extracorporeal membrane oxygenation (ECMO) or Impella treatment. The primary objective is to evaluate 28-day and ICU mortality, while secondary objectives include characterizing cardiac and non-cardiac complications, nutritional status changes, and hormonal dysregulations.
Eligibility Criteria
Inclusion Criteria: * Adult patients (age ≥ 18 years) * Treatment with ECMO and/or Impella support * Informed consent provided by the patients next of kin/ legal representative Exclusion Criteria: * None
Frequently Asked Questions
Who can join the NCT07885618 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiogenic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07885618 currently recruiting?
Yes, NCT07885618 is actively recruiting participants. Visit ClinicalTrials.gov or contact Gottsegen National Cardiovascular Institute to inquire about joining.
Where is the NCT07885618 trial being conducted?
This trial is being conducted at Budapest, Hungary.
Who is sponsoring the NCT07885618 clinical trial?
NCT07885618 is sponsored by Gottsegen National Cardiovascular Institute. The trial plans to enroll 160 participants.